In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adcetris Review Gives ODAC Chance To Apply Principles On Accelerated Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

BLAs for Seattle Genetics' antibody-drug conjugate to treat two rare lymphomas are based on single-arm trials, and the company has begun a confirmatory study for only one indication.
Advertisement

Related Content

Seattle Genetics Hoping Adcetris Label Expansion Trials Can Be Confirmatory
Seattle Genetics Hoping Adcetris Label Expansion Trials Can Be Confirmatory
Seattle Genetics Hoping Its Adcetris Trials Can Do Double Duty
Seattle Genetics Hoping Its Adcetris Trials Can Do Double Duty
New Avastin Breast Cancer Study Proposal Not Enough To Save Current Claim, ODAC Concludes
Seattle Genetics Files Antibody-Drug Conjugate BLA; Late August Approval Possible
FDA Will Make Advisory Committee Review Of Accelerated Approvals An Annual Event
FDA Will Make Advisory Committee Review Of Accelerated Approvals An Annual Event
Takeda Partners With Seattle Genetics On Lymphoma Candidate In Pivotal Trials

Topics

Advertisement
UsernamePublicRestriction

Register

PS072498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel